We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to ... Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. Show more
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention...
– Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral ischemic reperfusion induced acute kidney injury (AKI...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support further development across multiple indications...
– Oral presentation in addition to poster presentation announced January 30, 2024 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -5.93220338983 | 2.36 | 2.5199 | 1.7801 | 67626 | 2.03303682 | CS |
4 | -0.25 | -10.1214574899 | 2.47 | 2.96 | 1.7801 | 68430 | 2.44922495 | CS |
12 | -9.98 | -81.8032786885 | 12.2 | 25.26 | 1.7801 | 422130 | 5.83356687 | CS |
26 | -18.024 | -89.033787789 | 20.244 | 25.26 | 1.7801 | 273829 | 8.0028241 | CS |
52 | -32.88 | -93.6752136752 | 35.1 | 39.3 | 1.7801 | 237410 | 17.80819593 | CS |
156 | -8796.78 | -99.9747698602 | 8799 | 10237.5 | 1.7801 | 1290279 | 982.32522642 | CS |
260 | -8796.78 | -99.9747698602 | 8799 | 10237.5 | 1.7801 | 1290279 | 982.32522642 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions